Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
Open Access
- 9 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 12 (1), 1-8
- https://doi.org/10.1038/s41467-021-21134-2
Abstract
Dexamethasone can reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment were to be rolled out in the UK and globally, as well as the cost-effectiveness of implementing this intervention. Assuming SARS-CoV-2 exposure levels of 5% to 15%, we estimate that, for the UK, approximately 12,000 (4,250 - 27,000) lives could be saved between July and December 2020. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 (240,000 - 1,400,000) lives saved globally over the same time period. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, for example in low- and middle-income countries. Dexamethasone has been shown to have survival benefits for critically ill patients hospitalised with COVID-19 in the UK. Here, the authors estimated the number of lives that could be saved through a UK and global roll out of the drug and demonstrate that it is a cost-effective option.Funding Information
- DH | National Institute for Health Research
- RCUK | Medical Research Council
- Oxford University | Nuffield College, University of Oxford (COVID-19 Research Response Fund)
- Li Ka Shing Foundation
This publication has 16 references indexed in Scilit:
- Drug recently shown to reduce coronavirus death risk could run out, experts warnScience, 2021
- Estimating the burden of SARS-CoV-2 in FranceScience, 2020
- Coronavirus breakthrough: dexamethasone is first drug shown to save livesNature, 2020
- Dynamic interventions to control COVID-19 pandemic: a multivariate prediction modelling study comparing 16 worldwide countriesEuropean Journal of Epidemiology, 2020
- COVID-19 length of hospital stay: a systematic review and data synthesisPublished by Cold Spring Harbor Laboratory ,2020
- Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19Clinical Microbiology & Infection, 2020
- Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation ProtocolPublished by Cold Spring Harbor Laboratory ,2020
- Estimates of the severity of coronavirus disease 2019: a model-based analysisThe Lancet Infectious Diseases, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Economic evaluation of human papillomavirus vaccination in the United KingdomBMJ, 2008